Drugs / PA101
last change Jun 2016 re-read 3 minutes ago

PA101

Developed for
indolent systemic mastocytosis
Investigated by
Patara Pharma

Trials 1

201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02478957 Jun 2015 → Mar 2016 indolent systemic mastocytosis Patara Pharma Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PA101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02478957 ↗
Route Inhaled “administered via inhalation” NCT02478957 ↗